New hope for patients whose stomach cancer stopped responding to standard drug
NCT ID NCT06208748
Summary
This study is testing whether adding a new drug called bezuclastinib to an existing cancer drug (sunitinib) can help control advanced gastrointestinal stromal tumors (GIST) that have started growing again on sunitinib alone. It will involve about 40 adult patients who have a specific genetic mutation in their cancer. The main goal is to see how long the combination can keep the cancer from getting worse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL STROMAL TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111, United States
-
Oregon Health & Science University
Portland, Oregon, 97239, United States
-
Sylvester Comprehensive Cancer Center, University of Miami
Miami, Florida, 33136, United States
Conditions
Explore the condition pages connected to this study.